BDR Pharmaceutical has announced the launch of a new drug Palbociclib with the brand name 'BDPALBO' which is for advanced treatment of metastatic breast cancer in India. The Indian government has permitted the drug’s usage in the country.
BDR Pharma said, a non-specific form of Palbociclib obtainable in India will benefit many patients with (HR+) (HER2-) metastatic or advanced breast cancer who could not pay or were incapable to get access to the innovator's medicine.
The advent of this treatment will aid breast cancer patients to live with the disease at a much more reasonable rate. It will be made available online in three strengths, i.e., 125mg, 100mg, and 75mg capsules costing 3,150 for 75 mg, 3,600 for 100 mg, and 4,464 for 125 mg.
In 2020, 2.3 million women internationally were diagnosed with breast cancer, and 685000 people died from it, as per World Health Organization (WHO).
According to Sun Pharma, the largest pharmaceutical business in India by revenue, 0.21 million additional female patients are diagnosed with breast cancer each year, making it the most common type of cancer in the country. About half of all patients have hormone receptor-positive breast cancer, the most common subtype of the disease.
According to Raheel Shah, Director of Business Development at BDR Group, the introduction of APATIDE is "hearsay evidence regarding our dedication in giving access to cheap medications without jeopardizing patients' wellbeing as well as academic standards."
The business produces cancer medications in India and specializes in the production of pharmaceutically active components and cutting-edge formulations.
“The key objective in introducing medicine in India was to guarantee that all of our patients could obtain top-notch medical care at an affordable price. He dismisses the idea of rivalry as well, stating that he will continue to focus on developing specialized products and setting trends. BDR Pharma is renowned for its oncology portfolio, which included the first-ever generic drugs to be introduced in India. "Our main edge is our recognition capacity, using challenging chemistry to find complex substances that we then sell ourselves," said Raheel Shah.
There is no point in complaining about the competition since, if you invent anything, you should feel confident in your ability to overcome any problem, Raheel further said in a statement.
Wednesday saw the launch of Palbociclib in India for people with advanced breast cancer, according to a separate announcement from Sun Pharmaceutical Industries Limited. The company will market the medication as PALENO 75 mg, 100 mg, and 125 mg.
For patients in the hospital with hormone receptor-positive, HER2 negative metastatic, or locally advanced breast cancer, palbociclib is approved by the USFDA, EMA, and CDSCO when used in conjunction with hormonal treatments.
